Comprehensive Neuropathologic Analysis of Genetic Prion Disease Associated With the E196K Mutation in PRNP Reveals Phenotypic Heterogeneity
|
|
- Kathlyn Evans
- 5 years ago
- Views:
Transcription
1 J Neuropathol Exp Neurol Copyright Ó 2011 by the American Association of Neuropathologists, Inc. Vol. 70, No. 3 March 2011 pp. 192Y200 ORIGINAL ARTICLE Comprehensive Neuropathologic Analysis of Genetic Prion Disease Associated With the E196K Mutation in PRNP Reveals Phenotypic Heterogeneity Sabina Eigenbrod, MD, Petra Frick, PhD, Armin Giese, MD, Gabi Schelzke, MD, Inga Zerr, MD, and Hans A. Kretzschmar, MD, FRCPath Abstract The genetic forms of human transmissible spongiform encephalopathies (TSEs) are linked to mutations in the gene encoding the prion protein (PRNP) and account for 10% to 15% of human TSE cases. Some are distinct with respect to clinical signs, disease onset/ duration, and diagnostic findings, whereas others closely resemble sporadic Creutzfeldt-Jakob disease (scjd). We report a comprehensive analysis of 4 patients carrying the rare E196K (GAGYAAG) mutation who presented with clinical features of CJD. To date, information on this PRNP mutation is limited to clinical and genetic data. Consequently, the E196K mutation could not be unequivocally assigned to human prion disease. We report histopathologic and biochemical findings in addition to clinical observations, thus providing a more comprehensive analysis of this presumably genetic prion disease. Our data indicate that (i) the E196K mutation is causally linked to human prion disease, (ii) there is a complex phenotypic spectrum of this mutation that includes nonspecific symptoms at onset and features typical of scjd during disease progression, and (iii) the corresponding histologic picture comprises both cases with atypical neuropathology and cases that closely resemble subtypes of scjd corresponding to the classification of Parchi et al, with subtle modifications in hippocampal regions CA1-4. From the Center for Neuropathology and Prion Research (SE, PF, AG, HK), Ludwig Maximilians University Munich, Munich, Germany; and National TSE Reference Center (GS, IZ), Department of Neurology, Georg August University Goettingen, Goettingen, Germany. Send correspondence and reprint requests to: Hans A. Kretzschmar, MD, FRCPath, Center for Neuropathology and Prion Research, Ludwig Maximilians University Munich, Feodor-Lynen-Str. 23, Munich, Germany; hans.kretzschmar@med.uni-muenchen.de This work was supported by the Robert Koch Institute through funds of the Federal Ministry of Health (Bundesgesundheitsministerium, Grant No ). Key Words: Creutzfeldt-Jakob disease, E196K, Prion, PRNP, PrP Sc, Transmissible spongiform encephalopathy. Transmissible spongiform encephalopathies (TSEs), or prion diseases, are a group of fatal neurodegenerative disorders that are caused by a conformational conversion of the normal cellular form of the prion protein (PrP C ) to the misfolded isoform, designated PrP Sc (1Y3). Human prion diseases develop spontaneously, arise through genetic mutation (genetic/familial TSEs), or can be acquired through transmission from one host to another (acquired TSEs). Approximately 10% to 15% of human TSE cases are inherited and have been shown to segregate with mutations in the coding region of PRNP. To date, more than 30 PRNP mutations have been described. A number of these mutations are associated with distinct clinicopathologic phenotypes, including genetic Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler- Scheinker syndrome, and fatal familial insomnia (4Y6). The phenotypic heterogeneity of familial prion diseases is not solely dependent on the PRNP mutation but seems to be influenced by the polymorphic codon 129 genotype of the mutant and wild-type alleles and the haplotype background of the mutation. For example, the presence of methionine at the polymorphic codon 129 in coupling phase with asparagine at codon 178 typically results in the distinct clinical and pathologic features of fatal familial insomnia, whereas the same mutation in combination with valine at codon 129 leads to genetic CJD (7). Mutated PrP seems to be associated with a number of different pathogenic conformers that may differ in toxicity or neuropathologic targeting (8, 9). The product of the wild-type PRNP allele may also variably contribute to the disease process (10). It has been shown that polymorphism of codon 129 can influence the physicochemical properties of proteaseresistant PrP Sc (ie, the size of the protease-resistant fragment and the ratio of the different glycoforms) extracted from the brains of affected patients. In sporadic CJD (scjd) patients, 2 major human PrP Sc types (termed type 1 and type 2) that differ in electrophoretic mobility and the unglycosylated core fragments generated by treatment with proteinase K (PK) have been described (11Y14). Among the PRNP mutations identified to date, the point mutation E196K has been described in 4 reports (15Y18). The patients affected were either homozygous for methionine (15) or valine (16) at codon 129 in PRNP. Only 1 case heterozygous (M/V) at codon 129 was reported to the European Creutzfeldt-Jakob disease Surveillance System (19). The pathogenic significance of the E196K mutation with respect to a causal association with symptomatic disease, although very likely, has not been established. To date, all reports on this PRNP mutation have focused on the clinical findings and have not addressed the pathologic or biochemical attributes of this rare PRNP mutation. 192 J Neuropathol Exp Neurol Volume 70, Number 3, March 2011
2 J Neuropathol Exp Neurol Volume 70, Number 3, March 2011 E196K PRNP Mutation Neuropathology We performed a comprehensive study of 4 patients carrying the PRNP mutation E196K and report for the first time the histopathologic and biochemical features associated with the E196K mutation. MATERIALS AND METHODS Selection of Cases Four patients carrying PRNP mutation E196K had been identified as suspected CJD cases to the German CJD Surveillance Unit based on current clinical criteria for CJD (20Y22); the diagnoses were verified at autopsy (Table). Clinical data include results of physical examination, electroencephalography (EEG), magnetic resonance imaging (MRI), and evaluation of biomarkers in the cerebrospinal fluid (CSF) such as protein , Tau, neuron-specific enolase (NSE), and glial protein S100b (23Y26). The investigations were performed with informed consent and following all the institutional guidelines for experimental investigations with human specimens. Mutation Analysis and Genotyping Genomic DNA was extracted from blood samples and the coding region of PRNP was amplified by polymerase chain reaction. Subsequently, the complete open reading frame of PRNP was screened for mutations by direct sequencing using the automated LICOR 4200 DNA Analyzer/ Genetic Analyzer 3130 (Applied Biosystems, Lincoln, NE), as previously described (27, 28). Briefly, the amino acid at codon 129 in coupling with the mutation was determined by cloning. The polymerase chain reaction product was cleaved with EcoRI and XmaI. Subsequently, the large fragment was purified and cloned into the appropriate cleavage sites of pbluescriptiiks(j) (Stratagene, La Jolla, CA). The mutation and the respective codon 129 were verified by sequencing of 3 independent clones. Histopathologic and Immunohistochemical Analyses Autopsy and sampling of material for histopathologic analyses of various brain regions were performed as previously described (1). In addition, frozen samples of the frontal cortex, hippocampus, and cerebellum were preserved for biochemical analysis. Control brain tissue was obtained from corresponding brain regions of scjd patients with the MM 1, VV 2, and MV 2 subtypes. Brain material for histopathologic analysis was fixed in 4% buffered formalin, inactivated with 100% formic acid for 1 hour, fixed in formalin TABLE. Clinical Features of E196K Patients Patient 1 Patient 2 Patient 3 Patient 4 Codon 129 MM VV MV MM PrP Sc type Sex F M F F Age of onset, yr Disease duration, mo Initial symptoms Gait instability, confusion, Dementia Severe headache, Tremor impaired short-term memory depression, reduced appetite Initial clinical working Brainstem infarct, internal Wernicke encephalopathy NA Parkinson disease diagnosis hydrocephalus Final clinical diagnosis Possible CJD Probable CJD Probable CJD Probable CJD Progressive dementia + + NA + Myoclonus j Visual or cerebellar alterations Ataxia Ataxia, optical hallucinations, dysarthria/anarthria Pyramidal or extrapyramidal dysfunction Ataxia, dysarthria, dysphagia Ataxia, small step gait, bradykinesia, dysarthria, apraxia NA Rigor Pyramidal signs Rigor Akinetic mutism CJD typical EEG Severe grouped dysrhythmia, (periodic sharp waves) no typical signs of CJD CSF: proteins NA Tau j NA 19,537 pg/ml pg/ml NSE 30.5 Kg/L NA ng/ml NA S100 j NA 16.2 ng/ml j Other symptoms Peripheral polyneuropathy Incontinence NA Weight loss (diabetes) CJD typical MRI (hyperintense basal ganglia or cortex) NA Y mild cerebellar and parietal atrophy Y other: multilocular leukoencephalopathy + other: white matter lesions +, present; j, not conspicuous/absent; CJD, Creutzfeldt-Jakob disease; EEG, electroencephalograph; M, methionine; MRI, magnetic resonance imaging; NA, not available; NSE, neuron-specific enolase; V, valine. Ó 2011 American Association of Neuropathologists, Inc. 193
3 Eigenbrod et al J Neuropathol Exp Neurol Volume 70, Number 3, March Ó 2011 American Association of Neuropathologists, Inc.
4 J Neuropathol Exp Neurol Volume 70, Number 3, March 2011 and subsequently paraffin-embedded, and finally subjected to routine staining on a Benchmark staining machine with a standard 3,3-diaminobenzidine detection system, according to the manufacturer s instructions (Ventana Medical Systems, Tucson, AZ). Immunohistochemistry and paraffin-embedded tissue (PET) section blots were performed as previously described (1, 29), using PrP-specific antibody L42 (30). For the detection of hyperphosphorylated Tau protein, specific antibody AT8 (1:200; Perbio, Frankfurt, Germany) was used. Detection of >-synuclein was performed using antibody 15G7 (1:600; Novocastra, Newcastle upon Tyne, UK). Histologic sections were evaluated blinded and scored semiquantitatively for spongiosis, gliosis, and neuronal loss independently by 2 neuropathologists. PrP Sc levels in hippocampal regions CA1-4 and subiculum were quantified by densitometry using AIDA image analyzer (Raytest, Straubenhardt, Germany). Immunoblot Analyses Tissues from the frontal cortex, hippocampus, and the cerebellum were homogenized in 9 volumes (wt/vol) of lysis buffer containing 100 mmol/l sodium chloride, 10 mmol/l ethylenediaminetetraacetic acid, 0.5% sodium deoxycholate, 0.5% octylphenoxypolyethoxyethanol (Nonidet P-40), 100 mmol/l tris(hydroxymethyl)aminomethane, ph 6.9, at 37-C. After PK digestion (100 Kg/mL, 1 hour at 37-C), homogenates were subjected to sodium dodecylsulfateypolyacrylamide gel electrophoresis using precast 12% Bis-Tris gels (NuPAGE; Invitrogen, Karlsruhe, Germany). For classification and comparison of PrP Sc types, we used brain homogenates from scjd patients with PrP Sc types 1 (129 MM) and 2 (129 VV and 129 MV), respectively. The monoclonal antibody 3F4 (1: 3.000; DAKO, Hamburg, Germany), recognizing the epitope 109Y112 of human PrP, was used for immunodetection. Immunoreactivity was visualized by enhanced chemiluminescence (CDP-Star; Roche, Mannheim, Germany). PrP Sc glycoform ratios were evaluated densitometrically using AIDA image analyzer (Raytest). RESULTS Clinical Patient 1 A 77-year-old woman from the North of Germany was admitted to hospital with the working diagnosis of brainstem infarction/internal hydrocephalus by her general practitioner. At that point, the patient had a 6-week history of gait instability, confusion, and impaired short-term memory. She also had a history of diabetes mellitus accompanied by peripheral polyneuropathy. In the following 2 weeks, she showed progressive dementia and finally akinetic mutism. The EEG revealed severe grouped dysrhythmia, but periodic sharpwave complexes typical of CJD were absent. Examination of her CSF revealed slightly elevated NSE (30.5 Kg/L). There E196K PRNP Mutation Neuropathology was no record of other measurements of other CSF biomarkers associated with CJD. The patient was classified as possible CJD according to clinical criteria (20Y22). The family history was negative for dementia or a neurodegenerative disease. The patient s mother had died at the age of 83 with pneumonia, and her father had died at the age of 70 after a stroke. The patient died after a disease duration of 2 months. Direct sequencing of the PRNP gene open reading frame revealed the E196K mutation and homozygosity for methionine at codon 129. Patient 2 A 72-year-old man from Southern Germany was admitted to the hospital for etiologic clarification of dementia. The past medical history revealed chronic alcohol abuse. Initially, the patient was diagnosed with Wernicke encephalopathy. Two months later, his wife reported worsening of symptoms that included visual hallucinations, speech, and walking difficulties and incontinence. On physical examination, the patient was drowsy but awake. Neurologic examination demonstrated ataxia, rigor, dysarthria/anarthria, and myoclonus. Electroencephalography revealed typical periodic sharp-wave complexes. Cerebrospinal fluid proteins were detected, but there were no other relevant CSF protein measurements recorded. Magnetic resonance imaging showed mild cerebellar and parietal atrophy but no typical signs of CJD. The patient was classified as probable CJD according to clinical data. He developed akinetic mutism and died after a disease duration of 2.5 months. Direct sequencing of the PRNP gene open reading frame revealed the E196K and homozygosity for valine at codon 129. The family history was negative for dementia or a neurodegenerative disease. Patient 3 A 74-year-old woman from Southwest Germany first developed severe bifrontal headache paralleled by depression and loss of appetite. In the following months, she developed ataxia associated with dysarthria and dysphagia and, later, myoclonus and akinetic mutism. Because of her markedly impaired communication ability, dementia could not be assessed. The EEG indicated the appearance of periodic sharpwave complexes, and CSF levels of , Tau (19,537 pg/ml), NSE (113.8 ng/ml), and S100b (16.2 ng/ml) were elevated. Magnetic resonance imaging showed white matter lesions termed multilocular leukoencephalopathy and a general atrophy but no typical features of CJD. On the basis of clinical data, probable CJD was diagnosed before the genetic analysis was available. Direct sequencing of PRNP revealed heterozygosity for methionine and valine (MV) at codon 129. Subsequent cloning experiments demonstrated coupling of the E196K mutation with methionine at codon 129. The patient died after a disease duration of 4 months. There was no family history of a neurologic or psychiatric disorder. FIGURE 1. Neuropathologic features of Creutzfeldt-Jakob disease in the affected E196K subjects. Spongiform changes in hematoxylin and eosin (H&E)Ystained frontal cortex (scale bar = 100 Km), cerebellar (scale bar = 50 Km), and hippocampal sections (scale bar = 100 Km) and detection of PrP Sc deposits using PrP-specific antibody L42. Left column indicates Patient 1; middle column, Patient 2; right column, Patient 4. Ó 2011 American Association of Neuropathologists, Inc. 195
5 Eigenbrod et al J Neuropathol Exp Neurol Volume 70, Number 3, March 2011 Patient 4 A 69-year-old woman from Eastern Germany had a 6-month history of tremor accompanied by signs of dementia for 3 weeks before she was hospitalized. On admission, she additionally showed rigor, bradykinesia, cogwheel phenomenon, and small step gait and was first diagnosed with Parkinson disease. The patient reported a lack of concentration and considerable weight loss without reduced appetite in the last months. The EEG showed triphasic waves predominantly on the right. Magnetic resonance imaging revealed signal hyperintensities in the frontoparieto-occipital cortex and in the basal ganglia, and white matter lesions and general atrophy were also observed. In the CSF, the proteins were detectable, and Tau was elevated (91200 pg/ml); S100 protein level was unremarkable. In the course of disease, she developed ataxia, dysarthria, and apraxia and finally showed the picture of akinetic mutism, with pyramidal and extrapyramidal signs as well as myoclonus. The clinical diagnosis was probable CJD. The patient died after a disease duration of 8 months. Direct sequencing of the PRNP gene open reading frame revealed the E196K mutation and homozygosity for methionine at codon 129. Importantly, there was a positive family history: the patient s brother was diagnosed with probable genetic CJD (E196K mutation) and died at age 50 years. Detailed clinical data are not available for this patient, and no autopsy was performed. Nevertheless, these data suggest autosomal dominant inheritance of this putative pathologic mutation. Neuropathologic and Immunohistochemical Findings Histologic examination of all 4 cases demonstrated morphologic and immunohistochemical features of CJD. The findings in Patients 1 (129 MM) and 3 (129 MV) resembled those of the scjd MM/MV 1 type with mild to severe spongiform degeneration, astrocytic gliosis, and focal loss of neurons, mainly affecting the cerebral cortex, basal ganglia, thalamus, and cerebellum (Fig. 1, left column); the brainstem was unaffected. In contrast, the hippocampal regions CA1-4, which are usually spared in the MM/MV 1 type (1), were also affected by mild spongiform changes (Fig. 1, left column). Immunohistochemistry revealed a synaptic pattern of PrP Sc deposition in the affected areas including regions CA1-4 of the hippocampus (Fig. 1, left). The latter was even more obvious on PET blot sections (Fig. 2A). Patient 3 additionally showed a distinct microvasculopathy in the white matter, but the neuropathologic findings were similar to those in Patient 1 (not shown). Patient 2 (129 VV) had mild to moderate spongiform degeneration, astrocytic gliosis, and neuronal loss with laminar distribution in the deep cortical layers as well as prominent involvement of basal ganglia, thalamus, cerebellum, and brainstem nuclei (Fig. 1, middle column). The hippocampus, which is characteristically involved in the VV 2 subtype (1), was severely affected (Fig. 1, middle column). Immunostaining revealed synaptic and perineuronal PrP Sc deposits in the affected areas, predominantly in the deep cortical layers and the hippocampus. The cerebellum showed intense plaquelike PrP Sc deposits not only in the molecular and granular 196 FIGURE 2. Paraffin-embedded tissue (PET) blot analysis and quantification of PrP Sc deposits in the hippocampus of E196K patients and corresponding sporadic Creutzfeldt-Jakob disease (scjd) controls. (A) PrP Sc deposits in the hippocampus including regions CA1-4 compared with scjd subtype MM 1 and VV 2 controls. The black line in the scjd MM 1 control indicates the typical border between strong PrP Sc deposits in the subiculum (S) in contrast to the almost spared regions CA1-4. (B) Densitometric quantification of PrP Sc deposits in regions CA1-4 of MM/MV subjects normalized to the intensity of the subiculum (S). (C) Corresponding quantification of PrP Sc deposits in regions CA1-4 of VV subjects. Black bars indicate E196K cases; empty bars, scjd controls. cell layers but also in the white matter (Fig. 1, middle column). Involvement of the hippocampus was also demonstrated on PET blot sections (Fig. 2A). Patient 4 (129 MM) showed a different pattern: spongiform changes, gliosis, and neuronal loss were more severe but in general followed the same morphology and distribution as in Patients 1 and 3 (Fig. 1, right column). There was also mild microvasculopathy in the white matter. Immunohistochemistry displayed clear synaptic PrP Sc staining in the affected areas including the CA1-4 regions of the hippocampus, additionally combined with plaquelike PrP Sc deposits in the cortex and cerebellum (Fig. 1, right column). Large confluent vacuoles with perivacuolar PrP Sc staining were absent in all cortical layers. In contrast, the cerebellum had minor synaptic PrP Sc deposits in the molecular and granular cell layers but also showed a small number of focal plaquelike PrP Sc deposits in the molecular layer. Involvement of the hippocampal regions CA1-4 was confirmed in the PET blot (Fig. 2A). Densitometric quantification of PrP Sc in the hippocampus revealed markedly increased PrP Sc deposits in MM/MV patients carrying the E196K mutation (Patients 1, 3, and 4) versus MM/MV scjd control cases (Fig. 2B). This was also seen in Patient 2 (Fig. 2C); however, for codon Ó 2011 American Association of Neuropathologists, Inc.
6 J Neuropathol Exp Neurol Volume 70, Number 3, March 2011 E196K PRNP Mutation Neuropathology 129 VV patients, the CA1-2 region is also more affected in scjd (1). All cases were additionally examined for possible coexistent synucleinopathies and/or tauopathies. Immunohistochemistry using an antiysynuclein antibody was negative for pathologic deposits in all patients, No hyperphosphorylated tau-positive structures other than very few neurofibrillary tangles in the transentorhinal region of Patients 2 and 4 (corresponding to Braak stage I [31]) were detected (not shown). Biochemical Analysis of the E196K Mutation in PRNP The presence of PrP Sc was demonstrated by Western blot analysis in 3 different brain regions (frontal cortex, cerebellum, and hippocampus) in the 4 patients (Figs. 3 and 4). According to the Western blot classification of PrP Sc types by Parchi et al (11, 12), the PK-resistant PrP (PrP27-30) found in Patients 1 (129 MM) and 3 (129 MV) was PrP Sc type 1 (Figs. 3A, C), whereas Patient 2 (129 VV) presented with PrP Sc type 2 (Fig. 3B). For Patient 1, Western blot analysis in the cerebellum consistently resulted in poor band quality, which we attributed to tissue preservation because this case was otherwise indistinguishable from Case 3. Notably, Western blot analysis of the neuropathologically atypical Patient 4 (129 MM) revealed PrP Sc type 2 in all samples and, in addition, PrP Sc type 1 in the frontal cortex (Fig. 3D, lane 4) and the occipital lobe (not shown). Importantly, this patient does not resemble the scjd cases with so-called mixed phenotype and coexistence of PrP Sc types 1 and 2 (13), which typically have PrP Sc type 1 in the cerebellum and perivacuolar deposits associated with confluent vacuoles in the cortex, whereas this patient had PrP Sc type 2 in the cerebellum FIGURE 3. Western blot analysis of proteinase K (PK)Ytreated homogenates extracted from 3 different brain regions from the 4 affected E196K subjects. (AYD) Frontal cortex homogenates from sporadic Creutzfeldt-Jakob disease (scjd) subtypes classified as MM 1 (lane 1), VV 2 (lane 2), and MV 2 (lane 3) were used as controls. PK-resistant PrP from Patient 1 (A), Patient 2 (B), Patient 3 (C), and Patient 4 (D). Positions of the molecular mass markers are indicated (kda). Cb indicates cerebellum; Fx, frontal cortex; Hip, hippocampus. FIGURE 4. Relative abundance of the 3 glycoforms of proteinase K(PK)Yresistant PrP in the 4 patients carrying the E196K mutation versus sporadic Creutzfeldt-Jakob disease (scjd) controls (Co). The relative abundance of the diglycosylated (upper) band is depicted in white, the monoglycosylated (middle) band is shown in gray, and the nonglycosylated (lower) band is shown in black. Proportions of nonglycosylated bands were analyzed using Student t test. ***, p G 0.001; *, p G (Fig. 3D) and plaquelike deposits in the cortex (Fig. 5). Densitometric analysis of the PK-resistant bands showed glycoform ratios different from those found in scjd cases with underrepresentation of nonglycosylated forms in all brain regions in all 4 E196K patients irrespective of the PrP Sc type and neuropathologic phenotype (Figs. 3 and 4). Statistical analysis revealed a significant underrepresentation of nonglycosylated forms in all brain regions in all 4 patients compared with the respective scjd controls (Patients 1, 2, and 3: p G 0.001, Patient 4: p G 0.05). DISCUSSION Little information has been published regarding the E196K mutation, and in previous reports, only clinical data were available (15Y18). Thus, a definite diagnosis of CJD, which requires autopsied brain material, was not feasible. The cases reported previously were thus classified as probable CJD according to available clinical data. Consequently, the E196K mutation could not be unequivocally assigned to human prion disease. According to the Diagnostic Criteria Guidance from the Advisory Committee on Dangerous Pathogens TSE Working Group ( consum_dh/groups/dh_digitalassets/@dh/@ab/documents/ digitalasset/dh_ pdf), Definite genetic TSE requires a neuropathological confirmation of TSE, plus either definite TSE in a first degree relative (i.e., a parent, child or sibling), or a pathogenic prion protein gene (PRNP) mutation. We are the first to provide a neuropathologic confirmation of TSE in patients with the E196K mutation (based on histopathologic, immunohistochemical, and biochemical results); thus, our data confirm that E196K results in genetic prion disease. Generally, the clinical picture in our 4 patients was initially characterized by nonspecific symptoms including behavioral abnormalities at disease onset that led to initial diagnoses of Parkinson disease, Wernicke encephalopathy, Ó 2011 American Association of Neuropathologists, Inc. 197
7 Eigenbrod et al J Neuropathol Exp Neurol Volume 70, Number 3, March 2011 FIGURE 5. Immunohistochemistry for pathological PrP deposition in Case 4. (AYC) PrP deposits in the frontal cortex. A predominantly synaptic deposition pattern in the gray matter can be seen with focal plaquelike deposits. Panels (B) and (C) show larger magnifications of the areas indicated in (A) with a lined box (B) and dashed box (C), respectively. (DYF) Focal synaptic and small plaquelike deposits in the cerebellar cortex. Scalebar: (A, D) = 200 Km; scalebar: (BYC, F) = 20 Km, scalebar: (E) = 50 Km. and brainstem infarction/internal hydrocephalus. This nonspecific initial picture is consistent with the previous reports, but nonspecific symptoms at onset are common in scjd and sometimes lead to alternative clinical diagnoses. Although the number of cases we analyzed is small, frequent occurrence of alternative initial clinical diagnoses seems unusual to us; as the disease progressed, the patients developed typical features of CJD. Information on additional patients without neuropathologic investigations is provided elsewhere (Schelzke et al, unpublished data). Immunohistochemical analysis ruled out an underlying >-synucleinopathy that could potentially influence the initial clinical picture, which is of particular interest with respect to Patient 4 who showed symptoms suggestive of Parkinson disease. Similarly, there was only minor tau pathology in Patients 2 and 4, making it unlikely that there was a contribution of these changes to the clinical manifestations in these patients. These observations suggest that the nonspecific clinical symptoms at the disease onset were not secondary to other neurodegenerative disease processes. However, Patient 3 had signs suggestive of microvasculopathy, and Patient 4 additionally had white matter lesions on MRI; therefore, we cannot exclude the possibility that the initial clinical syndrome, especially the parkinsonism in Patient 4 (32), was at least partially related to vascular changes in these patients. 198 Ó 2011 American Association of Neuropathologists, Inc.
8 J Neuropathol Exp Neurol Volume 70, Number 3, March 2011 The median onset of disease in the affected E196K subjects was 72 T 3.4 years (mean T SD), which is approximately 10 years later than reported for other point mutations in the PRNP gene, including the most common mutation E200K (19). This finding is consistent with previous reports (15Y18). The mean duration of disease was 4 T 2.7 months, which is shorter than that reported for other genetic TSEs ranging from 5 to 40 months (19). Thus, the affected E196K subjects had a later disease onset along with shorter disease duration. The extensive assessment of genetic and neuropathologic findings in combination with the biochemically determined PrP Sc type in scjd patients has led to a comprehensive classification that includes 6 scjd PrP Sc subtypes (1) and also accounts for mixed phenotypes in an updated classification (13). According to this widely accepted classification of scjd cases, we found that Patients 1 and 3 were closely related with the scjd MM/MV 1, Patient 2 was closely related with the scjd VV 2 subtype, whereas Patient 4 had an atypical phenotype. Densitometric analysis of the PK-resistant bands revealed a significant underrepresentation of the nonglycosylated form in all brain regions in all 4 patients carrying the E196K mutation, irrespective of the PrP Sc type and neuropathologic phenotype. Such a marked underrepresentation of the nonglycosylated form relative to the diglycosylated and monoglycosylated form is not pathognomonic for the E196K mutation as it has previously been observed in subjects with a D178N mutation coupled with methionine codon at position 129 in PRNP (33). More precisely, the classic scjd VV 2 subtype usually presents with spongiform changes and plaquelike/perineuronal PrP Sc deposits predominantly in the deep cortical layers, hippocampal region CA4, and the cerebellum, whereas the scjd MM/MV 1 subtype usually shows spongiform changes throughout all cortical layers as well as synaptic PrP Sc staining. Patients 1, 2, and 3 closely resemble the picture typically seen in the scjd subtypes of the corresponding codon 129 genotype (1), indicating that the phenotype associated with the E196K mutation in these 3 patients is determined by the polymorphic codon 129. Codon 129 polymorphism can influence the disease phenotype as best described for the D178N mutation presenting as fatal familial insomnia when coupled with methionine and as genetic CJD when coupled with valine at codon 129 in PRNP (7). In addition to this overall similarity to scjd, the present study indicates that the E196K mutation severely affects the hippocampal CA1-4 regions. In summary, our findings indicate that the histopathology associated with this rare PRNP mutation comprises both cases with atypical neuropathology and cases that closely resemble subtypes of scjd corresponding to the classification of Parchi et al (1) with subtle modifications in the hippocampal regions CA1-4. ACKNOWLEDGMENTS The authors thank Eva Grasbon-Frodl and Rüdiger Schmalzbauer for providing the technical basis regarding sequencing and initial summary of the relevant literature, E196K PRNP Mutation Neuropathology respectively. Elzbieta Staniszewski, Ursula Jung, and Gertrud Kwiatkowski are gratefully acknowledged for expert technical assistance. REFERENCES 1. Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999;46:224Y33 2. Horwich AL, Weissman JS. Deadly conformationsvprotein misfolding in prion disease. Cell 1997;98:499Y Prusiner SB. Prions. Proc Natl Acad Sci U S A 1998;95:13363Y83 4. Lugaresi E, Medori R, Montagna P, et al. Fatal familial insomnia and dysautonomia with selective degeneration of thalamic nuclei. N Engl J Med 1986;315:997Y Brown P, Cervenáková L, Boellaard JW, et al. Identification of a PRNP gene mutation in Jakob s original Creutzfeldt-Jakob disease family. Lancet 1994;344:130Y31 6. Hainfellner JA, Brantner-Inthaler S, Cervenáková L, et al. The original Gerstmann-Sträussler-Scheinker family of Austria: Divergent clinicopathological phenotypes but constant PrP genotype. Brain Pathol 1995; 5:20 7. Goldfarb LG, Petersen RB, Tabaton M, et al. Fatal familial insomnia and familial Creutzfeldt-Jakob disease: Disease phenotype determined by a DNA polymorphism. Science 1992;258:806Y8 8. Piccardo P, Dlouhy SR, Lievens PM, et al. Phenotypic variability of Gerstmann-Sträussler-Scheinker disease is associated with prion protein heterogeneity. J Neuropathol Exp Neurol 1998;57:979Y88 9. Parchi P, Chen SG, Brown P, et al. Different patterns of truncated prion protein fragments correlate with distinct phenotypes in P102L Gerstmann-Sträussler-Scheinker disease. Proc Natl Acad Sci U S A 1998;95:8322Y Chen SG, Parchi P, Brown P, et al. Allelic origin of the abnormal prion protein isoform in familial prion diseases. Nat Med 1997;3:1009Y Parchi P, Castellani R, Capellari S, et al. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol 1996;39: 767Y Parchi P, Capellari S, Chen SG, et al. Typing prion isoforms. Nature 1997;386:232Y Parchi P, Strammiello R, Notari S, et al. Incidence and spectrum of sporadic Creutzfeldt-Jakob disease variants with mixed phenotype and co-occurrence of PrP Sc types: An updated classification. Acta Neuropathol 2009;118:659Y Notari S, Capellari S, Giese A, et al. Effects of different experimental conditions on the PrP Sc core generated by protease digestion: Implications for strain typing and molecular classification of CJD. J Biol Chem 2004;279:16797Y Peoc h K, Manivet P, Beaudry P, et al. Identification of three novel mutations (E196K, V203I, E211Q) in the prion protein gene (PRNP) in inherited prion diseases with Creutzfeldt-Jakob disease phenotype. Hum Mutat 2000;15: Tumani H, Windl O, Kretzschmar HA, et al. Clinically atypical CJD: Diagnostic relevance of cerebrospinal fluid markers and molecular genetic analysis? [in German] Dtsch Med Wochenschr 2002;127:318Y Clerici F, Elia A, Girotti F, et al. Atypical presentation of Creutzfeldt- Jakob disease: The first Italian case associated with E196K mutation in the PRNP gene. J Neurol Sci 2008;275:145Y Béjot Y, Osseby GV, Caillier M, et al. Rare E196K mutation in the PRNP gene of a patient exhibiting behavioral abnormalities. Clin Neurol Neurosurg 2010;12:244Y Kovács GG, Puopolo M, Ladogana A, et al. EUROCJD. Genetic prion disease: The EUROCJD experience. Hum Genet 2005;118:166Y WHO. Human transmissible spongiform encephalopathies. Wkly Epidemiol Rec 1998;73:361Y Zerr I, Pocchiari M, Collins S, et al. Analysis of EEG and CSF proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000;55:811Y Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain 2009;132: 2659Y68 Ó 2011 American Association of Neuropathologists, Inc. 199
9 Eigenbrod et al J Neuropathol Exp Neurol Volume 70, Number 3, March Mokuno K, Kato K, Kawai K, et al. Neuron specific enolase and S-100 protein levels in the cerebrospinal fluid of the patients with various neurological diseases. J Neurol Sci 1983;60:443Y Hsich G, Kenney K, Gibbs CJ, et al. The brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 1996;335:924Y Zerr I, Bodemer M, Weber T. The brain protein and transmissible spongiform encephalopathy. N Engl J Med 1997;336: Zerr I, Bodemer M, Gefeller O, et al. Detection of protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol 1998;43:32Y Windl O, Dempster M, Estibeiro JP, et al. Genetic basis of Creutzfeldt- Jakob disease in the United Kingdom: A systematic analysis of predisposing mutations and allelic variation in the PRNP gene. Hum Genet 1996; 98:259Y Grasbon-Frodl E, Lorenz H, Mann U, et al. Loss of glycosylation associated with the T183A mutation in human prion disease. Acta Neuropathol 2004;108:476Y Schulz-Schaeffer WJ, Tschoke S, Kranefuss N, et al. The paraffinembedded tissue blot detects PrP(Sc) early in the incubation time in prion diseases. Am J Pathol 2000;156:51Y Vorberg I, Buschmann, A, Harmeyer S, et al. A novel epitope for the specific detection of exogenous prion proteins in transgenic mice and transfected murine cell lines. Virology 1999;255:26Y Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239Y Sibon I, Tison F. Vascular parkinsonism. Review. Curr Opin Neurol 2004;17:49Y Parchi P, Capellari S, Chin S, et al. A subtype of sporadic prion disease mimicking fatal familial insomnia. Neurology 1999;52:1757Y Ó 2011 American Association of Neuropathologists, Inc.
Creutzfeldt-Jakob Disease with a Codon 210 Mutation: First Pathological Observation in a Japanese Patient
CASE REPORT Creutzfeldt-Jakob Disease with a Codon 210 Mutation: First Pathological Observation in a Japanese Patient Yasutaka Tajima 1, Chika Satoh 1, Yasunori Mito 1 and Tetsuyuki Kitamoto 2 Abstract
More informationCREUTZFELDT-JAKOB DISEASE (CJD), CLASSIC
CREUTZFELDT-JAKOB DISEASE (CJD), CLASSIC SPADIC CREUTZFELDT-JAKOB DISEASE (SCJD) Case definition CONFIRMED CASE Neuropathologically and/or immunocytochemically and/or biochemically confirmed, through observation
More informationPrion diseases or transmissible spongiform encephalopathies (TSEs)
Prion diseases or transmissible spongiform encephalopathies (TSEs) rare progressive neurodegenerative disorders that affect both humans and animals. They are distinguished by long incubation periods, characteristic
More informationAppendix B: Provincial Case Definitions for Reportable Diseases
Ministry of Health and Long-Term Care Infectious Diseases Protocol Appendix B: Provincial Case Definitions for Reportable Diseases Disease: Creutzfeldt-Jakob Disease, all types Revised Creutzfeldt-Jakob
More informationHuman prion disease in Piemonte and Valle d Aosta, Italy: the experience of the reference center for human prion disease and a case description.
Human prion disease in Piemonte and Valle d Aosta, Italy: the experience of the reference center for human prion disease and a case description. Enterprise Interest None Introduction The Centro regionale
More informationGlossary of relevant medical and scientific terms
Glossary of relevant medical and scientific terms Alzheimer's disease The most common dementing illness of the elderly in the UK. The neuropathology of Alzheimer's disease is significantly different from
More information( Sporadic Creutzfeldt-Jakob disease ) ( Infection control ) ( Decontamination )
2005 6 42-47 ( Sporadic Creutzfeldt-Jakob disease ) ( Infection control ) ( Decontamination ) 920 myoclonus ) 60 5 ( progressive dementia and (muscle power 4~4+) (588 mg/dl) (26 mg/dl) 72 (disorientation)
More informationPrion diseases are inevitably fatal neurodegenerative conditions
CASE REPORT A Prion Disease Possible Gerstmann-Straussler-Scheinker Disease A Case Report Ayse Aralasmak, MD,* Barbara J. Crain, MD, PhD, Wen-Quan Zou, MD, PhD, and David M. Yousem, MD, MBA* Summary: A
More informationClinical Features of Sporadic Fatal Insomnia
DIAGNOSIS UPDATE Clinical Features of Sporadic Fatal Insomnia Jed A. Barash, MD Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA Recent advances in neuropathology, genotyping,
More informationSporadic CJD in a patient with relapsing-remitting multiple sclerosis on an immunomodulatory treatment
Acta Neurol. Belg., 2011, 111, 232-236 Sporadic CJD in a patient with relapsing-remitting multiple sclerosis on an immunomodulatory treatment Tereza Gabelić 1,2, Mario Habek 1,2, inga Zerr 3, Joanna Gawinecka
More informationdoi: /brain/awq234 Brain 2010: 133;
doi:10.1093/brain/awq234 Brain 2010: 133; 3030 3042 3030 BRAIN A JOURNAL OF NEUROLOGY Agent strain variation in human prion disease: insights from a molecular and pathological review of the National Institutes
More informationCreutzfeldt-Jakob Disease: Spectrum of Magnetic Ressonance Imaging findings
Creutzfeldt-Jakob Disease: Spectrum of Magnetic Ressonance Imaging findings Poster No.: C-0486 Congress: ECR 2014 Type: Educational Exhibit Authors: F. M. P. D. Carvalho, E. Rosado, J. Marçalo, M. Bousende,
More informationClinical findings and diagnostic tests in the MV2 subtype of sporadic CJD
doi:10.1093/brain/awl123 Brain (2006), 129, 2288 2296 Clinical findings and diagnostic tests in the MV2 subtype of sporadic CJD Anna Krasnianski, 1 Walter J. Schulz-Schaeffer, 2 Kai Kallenberg, 3 Bettina
More information1. Introduction. 2. Patient and Methods. Mitrova Eva *, Belay Girma, Slivarichova Zakova Dana, Stelzer Martin. Clinical Medicine Journal.
Clinical Medicine Journal Vol. 1, No. 3, 2015, pp. 101-105 http://www.aiscience.org/journal/cmj The First Case of Genetic Creutzfeldt-Jakob Disease with the Rare Mutation R208H, Methionine/ Valine Heterozygous
More informationhttps://doi.org/ /doctor.r13 Final publication is available at
Specific clinical signs and Titlecourse in sporadic Creutzfeldt-Jako symptom 文 ) Author(s) Nakatani, Eiji Citation Kyoto University ( 京都大学 ) Issue Date 2016-11-24 URL https://doi.org/10.14989/doctor.r13
More informationCREUTZFELDT-JAKOB DISEASE (CJD)
Cause/Epidemiology CREUTZFELDT-JAKOB DISEASE (CJD) The agent causing CJD and other human transmissible spongiform encephalopathy (TSE) has not yet been definitively identified. It was originally thought
More informationThe New England Journal of Medicine
Brief Report PRION PROTEIN CONFORMATION IN A PATIENT WITH SPORADIC FATAL INSOMNIA JAMES A. MASTRIANNI, M.D., PH.D., RANDAL NIXON, M.D., PH.D., ROBERT LAYZER, M.D., GLENN C. TELLING, PH.D., DONG HAN, M.S.,
More informationFatal familial insomnia
International Journal of Scientific and Research Publications, Volume 8, Issue 2, February 2018 560 Fatal familial insomnia Hassan I. Osman *(1), Mazin. S. Abdalla (2) * (1) Department of Physiology, Napata
More informationClinical and Familial Characteristics of Ten Chinese Patients with Fatal Family Insomnia *
471 Biomed Environ Sci, 2012; 25(4): 471-475 Letters Clinical and Familial Characteristics of Ten Chinese Patients with Fatal Family Insomnia * SHI Qi 1, CHEN Cao 1, GAO Chen 1, TIAN Chan 1, ZHOU Wei 1,
More informationRelationships between Clinicopathological Features and Cerebrospinal Fluid Biomarkers in Japanese Patients with Genetic Prion Diseases
Relationships between Clinicopathological Features and Cerebrospinal Fluid Biomarkers in Japanese Patients with Genetic Prion Diseases Maya Higuma 1, Nobuo Sanjo 1 *, Katsuya Satoh 2, Yusei Shiga 3, Kenji
More informationGenetic CJD INFORMATION SHEET 2 JANUARY Introduction to genetic CJD. Inheriting a risk of CJD
INFORMATION SHEET 2 JANUARY 2008 Genetic CJD Genetic CJD (previously called familial CJD and sometimes referred to as inherited CJD) is an inherited form of Creutzfeldt-Jakob disease, which belongs to
More informationHEALTHCARE PROVIDER EDITION IN THIS ISSUE WINTER 2012 INTRODUCTION
IN THIS ISSUE Introduction CJD Information & Update The Second Case of Variant CJD in Canada Genetics in CJD Diagnosis and Surveillance You Asked Us Important Announcement: Additional CSF Protein Tests
More informationBiol212 Biochemistry of Disease Neurological Disorders: Prions
Biol212 Biochemistry of Disease Neurological Disorders: Prions Prions Transmissible spongiform encephalopathies (TSEs) are diseases of the central nervous system caused by unconventional infectious agents,
More informationDevelopment of an Intravitam Diagnostic Test for Human Prion Diseases using Real Time QuIC and Enhanced QuIC Assays
11 th Annual CJD Foundation Family Conference Development of an Intravitam Diagnostic Test for Human Prion Diseases using Real Time QuIC and Enhanced QuIC Assays Christina D. Orrú, PhD orruc@niaid.nih.gov
More informationDevelopment of an ante-mortem & pre-symptomatic diagnostic test for human prion diseases using RT-QuIC & equic assays
Development of an ante-mortem & pre-symptomatic diagnostic test for human prion diseases using RT-QuIC & equic assays Rocky Mountain Labs National Institute for Allergy & Infectious Diseases 12 th Annual
More informationMandate and New Programs
National Prion Disease Pathology Surveillance Center Departments of Pathology and Neurology Mandate and New Programs National Prion Disease Pathology Surveillance Center Presented by Jiri G. Safar July
More informationClinicopathologic and genetic aspects of hippocampal sclerosis. Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA
Clinicopathologic and genetic aspects of hippocampal sclerosis Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA The hippocampus in health & disease A major structure of the medial temporal
More informationFamilial Prion Disease Cases Without Mutation in PRNP Gene
Familial Prion Disease Cases Without Mutation in PRNP Gene Sahar Jelodari-Mamaghani 1, Gholam Ali Shahidi 2, Mohammad Roohani 2, Farzad Sina 2, * 1 School of Biology, University College of Science, University
More informationFATAL FAMILIAL INSOMNIA
Azienda ASL 9 TREVISO Presidio Ospedaliero di Treviso Dipartimento di Medicina Unità Operativa di Medicina Interna Seconda Responsabile dr Ignazio Roiter FATAL FAMILIAL INSOMNIA Dr I. ROITER FATAL FAMILIAL
More informationAlexander H Peden *, Deep P Sarode, Carl R Mulholland, Marcelo A Barria, Diane L Ritchie, James W Ironside and Mark W Head
Peden et al. Acta Neuropathologica Communications 2014, 2:152 RESEARCH Open Access The prion protein protease sensitivity, stability and seeding activity in variably protease sensitive prionopathy brain
More informationPrion diseases are neurodegenerative disorders that affect
Genetic influence on the structural variations of the abnormal prion protein Piero Parchi*, Wenquan Zou*, Wen Wang*, Paul Brown, Sabina Capellari*, Bernardino Ghetti, Nicolas Kopp, Walter J. Schulz-Schaeffer,
More informationSporadic Creutzfeldt-Jakob disease (CJD) is a rare and fatal
ORIGINAL RESEARCH B. Meissner K. Kallenberg P. Sanchez-Juan A. Krasnianski U. Heinemann D. Varges M. Knauth I. Zerr Isolated Cortical Signal Increase on MR Imaging as a Frequent Lesion Pattern in Sporadic
More informationDepartment of Neurology, Wolski Hospital, Warsaw, Poland 3
Signature: Pol J Radiol, 2012; 77(1): 63-67 Received: 2011.12.29 Accepted: 2012.01.19 Background Background: : Conclusions: Key words: PDF fi le: The value of magnetic resonance imaging in the early diagnosis
More informationAppendix A: Disease-Specific Chapters
Ministry of Health and Long-Term Care Infectious Diseases Protocol Appendix A: Disease-Specific Chapters Chapter: Creutzfeldt-Jakob Disease, all types Revised March 2017 Creutzfeldt-Jakob Disease, all
More informationEdinburgh Research Explorer
Edinburgh Research Explorer Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease Citation for published version: McGuire, LI, Peden, AH, Orrú, CD,
More informationMolecular classi cation of sporadic Creutzfeldt±Jakob disease
DOI: 10.1093/brain/awg125 Advanced Access publication April 8, 2003 Brain (2003), 126, 1333±1346 Molecular classi cation of sporadic Creutzfeldt±Jakob disease Andrew F. Hill, 1,4 Susan Joiner, 1 Jonathan
More informationNACC Neuropathology (NP) Diagnosis Coding Guidebook
Department of Epidemiology, School of Public Health and Community Medicine, University of Washington 4311 11 th Avenue NE #300 Seattle, WA 98105 phone: (206) 543-8637; fax: (206) 616-5927 e-mail: naccmail@u.washington.edu
More informationConsensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: an inter-rater
Edinburgh Research Explorer Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: an inter-rater study among surveillance centres in Europe and
More informationUse of and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease
744 Department of Neuroimmunology, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK E J Thompson The National Creutzfeldt-Jakob Disease Surveillance Unit, Western General
More informationA Case of Gerstmann-Sträussler-Scheinker Disease
CASE REPORT J Clin Neurol 2010;6:46-50 Print ISSN 1738-6586 / On-line ISSN 2005-5013 10.3988/jcn.2010.6.1.46 A Case of Gerstmann-Sträussler-Scheinker Disease Min Jeong Park, MD a ; Hee Young Jo, MD b ;
More informationsimilar version to the prion protein. Host proteins are correctly folded and prion proteins are
Background: Prions are infectious agents containing only protein (no nucleic acid). The host cell has a similar version to the prion protein. Host proteins are correctly folded and prion proteins are misfolded.
More informationCreutzfeldt-Jakob Disease
Creutzfeldt-Jakob Disease Other Dementias Introduction Alzheimer s disease is one type of a large group of disorders known as dementias. It is an irreversible disease of the brain in which the progressive
More informationGrand-round meeting for Dementia - A patient with rapidly progressing dementia. Dr. Ho Ka Shing Tuen Mun Hospital
Grand-round meeting for Dementia - A patient with rapidly progressing dementia Dr. Ho Ka Shing Tuen Mun Hospital Mr. Wong, 60 years old Security guard Ex-smoker for over 20 years, non-drinker Premorbid
More informationThe Carroll A. Campbell, Jr. Neuropathology Laboratory: A Tool for Dementia Discovery in South Carolina
The Carroll A. Campbell, Jr. Neuropathology Laboratory: A Tool for Dementia Discovery in South Carolina Pathology in the Cerebral Cortex H&E stain of mature neuritic plaque Modified Bielschowsky stain
More informationCREUTZFELDT-Jakob disease
OSERVATION Correlation of Diffusion-Weighted Magnetic Resonance Imaging With Neuropathology in Creutzfeldt-Jakob Disease Sanjay Mittal, MD; Peter Farmer, MD; Peter Kalina, MD; Peter. Kingsley, PhD; John
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Prion Diseases Permalink https://escholarship.org/uc/item/0ws8245k Journal CONTINUUM Lifelong Learning in Neurology, 21(6) ISSN 1080-2371
More informationPathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)
Pathogenesis of Degenerative Diseases and Dementias D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Dementias Defined: as the development of memory impairment and other cognitive deficits
More informationHerpesvirus Infections of the Central Nervous System
CNS Infections V Page 1 of 8 Herpesvirus Infections of the Central Nervous System HSV encephalitis Herpes B Virus infections Varicella-Zoster Virus infections Congenital CMV infection HSV Encephalitis
More informationNeurology Department, The First Hospital of China Medical University, Nanjing North Street 155, Shenyang, Liaoning Province, China
Psychiatric Symptoms as Bases for Differential Diagnosis of Pre-mortem Sporadic Creutzfeldt-Jakob Disease and Anti-N-Methyl D-aspartate Receptor Encephalitis Yujia Luo 1, Xi Cheng 1, Yang Jiao 2, Huibin
More informationClinical diagnosis and differential diagnosis of CJD and vcjd
APMIS 110: 88 98, 2002 Copyright C APMIS 2002 Printed in Denmark. All rights reserved ISSN 0903-4641 Clinical diagnosis and differential diagnosis of CJD and vcjd With special emphasis on laboratory tests
More informationCoexistence of protease sensitive and resistant prion protein in 129VV homozygous sporadic Creutzfeldt Jakob disease: a case report
Rodríguez-Martínez et al. Journal of Medical Case Reports 2012, 6:348 JOURNAL OF MEDICAL CASE REPORTS CASE REPORT Open Access Coexistence of protease sensitive and resistant prion protein in 129VV homozygous
More informationAntemortem Diagnostics in Prion Disease. Danielle Gushue. A thesis submitted in partial fulfillment of the requirements for the degree of
Antemortem Diagnostics in Prion Disease by Danielle Gushue A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science in Animal Science Department of Agricultural,
More information[ ] Creutzfeldt-Jakob (scjd) scjd. Creutzfeldt-Jakob. [DOI] /j.issn
Med J Chin PLA, Vol. 42, No. 5, May 1, 2017 445 Creutzfeldt-Jakob [ ] Creutzfeldt-Jakob (scjd) 53 scjd (DWI) 24h (EEG) 14-3-3 (PET-CT) 2 53 scjd 24 53 22 ( 2 3 ) DWI ( 58.3% 84.6% 94.7%) EEG ( 45.8% 62.7%
More informationEdinburgh Research Explorer
Edinburgh Research Explorer Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis Citation for published version: Sanchez-Juan, P, Sánchez-Valle, R, Green, A, Ladogana, A, Cuadrado-Corrales,
More informationABCD of CJD (the big picture of Creutzfeldt-Jakob disease)
ABCD of CJD (the big picture of Creutzfeldt-Jakob disease) Rolande D Amour, RN, MScN Canadian Dementia Resource and Knowledge Exchange Webinar, January 23, 2012 Presentation goals Explain: prion diseases
More informationNeuropathology of variant Creutzfeldt-Jakob disease
Acta Neurobiol. Exp. 2002, 62: 175-182 Neuropathology of variant Creutzfeldt-Jakob disease James W. Ironside, Mark W. Head, Linda McCardle and Richard Knight National Creutzfeldt-Jakob Disease Surveillance
More informationAuthor's response to reviews
Author's response to reviews Title: Novel mutation of the PRNP gene of a clinical CJD case Authors: Konstantina Kotta (ntina_kotta@yahoo.com) Ioannis Paspaltsis (ipaspalt@pharm.auth.gr) Sevasti Bostantjopoulou
More informationDetection of Pathologic Prion Protein in the Olfactory Epithelium in Sporadic Creutzfeldt Jakob Disease
original article Detection of Pathologic Prion Protein in the Olfactory Epithelium in Sporadic Creutzfeldt Jakob Disease Gianluigi Zanusso, M.D., Ph.D., Sergio Ferrari, M.D., Franco Cardone, Ph.D., Paolo
More informationCreutzfeldt-Jakob Disease Transmitted by Dura mater Graft Dr. Manuel Clavel, C/ Margenat 19, E Bellaterra (Barcelona) (Spain)
/ Short Report Eur Neurol 1996;36:239-240 M. Manuel Clavel P. Pablo Clavel Neurosurgery Service, Hospital General de Cataluna, Barcelona, Spain Creutzfeldt-Jakob Disease Transmitted by Dura mater Graft
More informationThe Spectrum of Age-Associated Astroglial Tauopathies. Dennis W. Dickson MD Department of Neuroscience Mayo Clinic, Jacksonville, FL
The Spectrum of Age-Associated Astroglial Tauopathies Dennis W. Dickson MD Mayo Clinic, Jacksonville, FL Thorn-shaped astrocytes TSA were first reported by Ikeda (1995), as tau-positive astrocytes in various
More informationCreutfeldt-Jakob draft policy December 2016
Creutfeldt-Jakob draft policy December 2016 Creutzfeldt-Jakob disease (CJD) is a devastating illness that is universally fatal. There is no treatment that can delay or prevent death. Because CJD is rare,
More informationDiffusion-Weighted MR Imaging in Biopsy-Proven Creutzfeldt-Jakob Disease
Diffusion-Weighted MR Imaging in iopsy-proven reutzfeldt-jakob Disease Hyo-heol Kim, MD 1 Kee-Hyun hang, MD 1 In han Song, PhD 1 Sang Hyun Lee, MD 1 ae Ju Kwon, MD 1 Moon Hee Han, MD 1 Sang-Yun Kim, MD
More informationPrion disease genetics
(2006) 14, 273 281 & 2006 Nature Publishing Group All rights reserved 1018-4813/06 $30.00 www.nature.com/ejhg REVIEW Simon Mead*,1 1 MRC Prion Unit, Department of Neurodegenerative Diseases, Institute
More informationDEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD
DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD OBJECTIVES Terminology/Dementia Basics Most Common Types Defining features Neuro-anatomical/pathological underpinnings Neuro-cognitive
More informationInherited Prion Disease A117V Is Not Simply a Proteinopathy but Produces Prions Transmissible to Transgenic Mice Expressing Homologous Prion Protein
Inherited Prion Disease A117V Is Not Simply a Proteinopathy but Produces Prions Transmissible to Transgenic Mice Expressing Homologous Prion Protein Emmanuel A. Asante, Jacqueline M. Linehan, Michelle
More informationCREUTZFELDT-JAKOB DISEASE: RECENT OBSERVATION AND DISCUSSION OF TWO CLINICAL CASES
Acta Medica Mediterranea, 2016, 32: 729 CREUTZFELDT-JAKOB DISEASE: RECENT OBSERVATION AND DISCUSSION OF TWO CLINICAL CASES GRACI DANIELA*, ALBA GIOVANNI*, BORSELLINO GASPARE, MANDRACCHIA RICCARDO, CUTRÒ
More informationDementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada
Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends
More informationDementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology
Dementia Stephen S. Flitman, MD Medical Director 21st Century Neurology www.neurozone.org Dementia is a syndrome Progressive memory loss, plus Progressive loss of one or more cognitive functions: Language
More informationReview Article ISSN : PRIONS-FRIENDS OR ENEMIES
www.ijapbr.com International journal of Applied Pharmaceutical and Biological Research, 2016;1(4):67-71 Review Article ISSN : 2456-0189 ABSRACT: PRIONS-FRIENDS OR ENEMIES BLESSY JACOB*, LATA KHANI BISHT,
More informationENCEPHALOPATHY RECOGNIZING METABOLIC AND ANOXIC CHANGES
ENCEPHALOPATHY RECOGNIZING METABOLIC AND ANOXIC CHANGES ENCEPHALOPATHY Encephalopathy is a general term that means brain disease, damage, or malfunction. The major symptom of encephalopathy is an altered
More informationSUPPLEMENTARY INFORMATION
doi:10.1038/nature10353 Supplementary Figure 1. Mutations of UBQLN2 in patients with ALS and ALS/dementia. (a) A mutation, c.1489c>t (p.p497s), was identified in F#9975. The pedigree is shown on the left
More informationCase 9 10/29/2018. CJD (Creutzfeldt -Jakob Disease) CJD (Creutzfeldt -Jakob Disease) CJD (Creutzfeldt -Jakob Disease)
CJD (Creutzfeldt -Jakob Disease) Rare fatal neurodegen dz caused by infectious protein Prion (lacks nucleic acid)- causes spongiform changes of the brain and neuronal death. 4 types: scjd- 85% of cases
More informationForm D1: Clinician Diagnosis
Initial Visit Packet Form D: Clinician Diagnosis NACC Uniform Data Set (UDS) ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by the clinician.
More informationAmyloid β accumulation in the CNS in human growth hormone recipients in the UK
Acta Neuropathol (2017) 134:221 240 DOI 10.1007/s00401-017-1703-0 ORIGINAL PAPER Amyloid β accumulation in the CNS in human growth hormone recipients in the UK Diane L. Ritchie 1 Peter Adlard 2 Alexander
More informationCJD DISEASE: Image Source: bestpractice.bmj.com
CJD DISEASE: Creutzfeldt-Jakob disease or CJD is when the central nervous system dysfunctions. Before CJ After CJ It is characterized by a rapidly progressive dementia which eventually leads to death.
More informationAmyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative
ORIGINAL RESEARCH E. Matsusue S. Sugihara S. Fujii T. Kinoshita T. Nakano E. Ohama T. Ogawa Cerebral Cortical and White Matter Lesions in Amyotrophic Lateral Sclerosis with Dementia: Correlation with MR
More informationVariant Creutzfeldt-Jakob disease
REVIEW ARTICLE Folia Neuropathol. Suppl. A, pp. 77 83 Copyright 2004 Via Medica ISSN 1641 4640 Variant Creutzfeldt-Jakob disease Robert Will National CJD Surveillance Unit, Western General Hospital, Edinburgh,
More informationImmuno-Real Time-PCR as a sensitive diagnostic tool: case of prion proteins.
Immuno-Real Time-PCR as a sensitive diagnostic tool: case of prion proteins. Virginie Ruelle and Benaissa ElMoualij. Center of Research on Prion Protein, University of Liège, Liège, Belgium Freising-Weihenstephan
More informationChronic Wasting Disease (CWD)
Blood Safety The American Red Cross (ARC) is denying blood donations from individuals who have spent six months or more in Europe since 1980, as well as that of any blood relative of a CJD victim. Sporadic
More informationPrions: The Protein of Your Nightmares
Verge 8 Passley Hargrove Prions: The Protein of Your Nightmares Dr. Stanley B. Prusiner was awarded the Nobel Prize in Physiology or Medicine in 1997 for his discovery of prions. Prions, which stand for
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Mok T, Jaunmuktane Z, Joiner S, et al. Variant Creutzfeldt
More informationDementia and Healthy Ageing : is the pathology any different?
Dementia and Healthy Ageing : is the pathology any different? Professor David Mann, Professor of Neuropathology, University of Manchester, Hope Hospital, Salford DEMENTIA Loss of connectivity within association
More informationCreutzfeldt-Jakob Disease Is A Rare Fatal Disease With No Treatment
ISPUB.COM The Internet Journal of Infectious Diseases Volume 6 Number 1 Creutzfeldt-Jakob Disease Is A Rare Fatal Disease With No Treatment M Rasheed, L Mimano Citation M Rasheed, L Mimano. Creutzfeldt-Jakob
More informationExtraneural Pathologic Prion Protein in Sporadic Creutzfeldt Jakob Disease
The new england journal of medicine original article Extraneural Pathologic Prion Protein in Sporadic Creutzfeldt Jakob Disease Markus Glatzel, M.D., Eugenio Abela, Manuela Maissen, M.S., and Adriano Aguzzi,
More informationRegistry of Creutzfeldt-Jakob disease and related disorders (19 years of activity: )
!!! "#$%&' ( )* +* ' &, --%". / & 0123&445467&6844& Registry of Creutzfeldt-Jakob disease and related disorders (19 years of activity: 1993-2011) Voluntary Notification: 1993-2000 Mandatory Notification:
More informationnumber Done by Corrected by Doctor Ashraf Khasawneh
number 3 Done by Mahdi Sharawi Corrected by Doctor Ashraf Khasawneh *Note: Please go back to the slides to view the information that the doctor didn t mention. Prions Definition: Prions are rather ill-defined
More informationCreutzfeldt-Jakob disease in Hungary
Original article Creutzfeldt-Jakob disease in Hungary Gábor G. Kovács, Katalin Majtényi Department of Neuropathology, National Institute of Psychiatry and Neurology, Budapest, Hungary Folia Neuropathol
More informationA Novel Prion Disease Associated with Diarrhea and Autonomic Neuropathy
The new england journal of medicine original article A Novel Prion Disease Associated with Diarrhea and Autonomic Neuropathy Simon Mead, M.D., Sonia Gandhi, M.D., Jon Beck, B.Sc., Diana Caine, Ph.D., Dilip
More informationvariant led to a premature stop codon p.k316* which resulted in nonsense-mediated mrna decay. Although the exact function of the C19L1 is still
157 Neurological disorders primarily affect and impair the functioning of the brain and/or neurological system. Structural, electrical or metabolic abnormalities in the brain or neurological system can
More informationChronic Traumatic Encephalopathy Provider and Parent Essentials
Chronic Traumatic Encephalopathy Provider and Parent Essentials Concussion Global Cast July 30, 2014 John Lockhart, MD Seattle Children s Hospital Chronic Traumatic Encephaly (CTE) Working Definition Chronic
More informationCreutzfeldt-Jakob disease (CJD)
Creutzfeldt-Jakob disease (CJD) A topic in the Alzheimer s Association series on understanding dementia. Dementia is a condition in which a person has significant difficulty with daily functioning because
More informationAutopsy Committee Sample Autopsy Case. Alzheimer Disease. Authors Ashley Thorburn, MD. Joseph E. Parisi, MD Autopsy Committee
Autopsy Committee Sample Autopsy Case Alzheimer Disease Authors Ashley Thorburn, MD Joseph E. Parisi, MD Autopsy Committee Clinical Summary: A 75-year-old man presented to his primary care physician with
More informationNB: A confirmed diagnosis of scjd can only made with brain tissue obtained upon autopsy
1 Creutzfeldt Jakob Disease: A Resource for Health Professionals Cases of suspect or probable Creutzfeldt Jakob Disease (CJD) should be reported to the Creutzfeldt Jakob Disease Surveillance System (CJDSS)
More informationNew Ways of Prion Disease Detection & Diagnosis
New Ways of Prion Disease Detection & Diagnosis Byron Caughey Rocky Mountain Labs National Institute for Allergy & Infectious Diseases National Institutes of Health BRAIN Contains ~1 billion neurons (nerve
More informationFamilial dystonia with cerebral calcification
Familial dystonia with cerebral calcification case report and genetic update M. Signaevski, A.K. Wszolek, A.J. Stoessel, R. Rademakers, and I.R. Mackenzie Vancouver General Hospital, BC, Canada Mayo Clinic
More informationNeuropathology of Neurodegenerative Disorders Prof. Jillian Kril
Neurodegenerative disorders to be discussed Alzheimer s disease Lewy body diseases Frontotemporal dementia and other tauopathies Huntington s disease Motor Neuron Disease 2 Neuropathology of neurodegeneration
More informationReport of the Guideline Development Subcommittee of the American Academy of Neurology
SPECIAL ARTICLE Evidence-based guideline: Diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease Report of the Guideline Development Subcommittee of the American Academy of Neurology
More informationDIAGNOSIS & TREATMENT OF HUMAN PRION DISEASES
DIAGNOSIS & TREATMENT OF HUMAN PRION DISEASES Richard Knight NCJDRSU / CCBS University of Edinburgh Scotland OUTLINE SOME GENERAL POINTS ABOUT DIAGNOSIS RECENT DIAGNOSTIC DEVELOPMENTS SOME GENERAL POINTS
More informationDiagnosis of Creutzfeldt-Jakob disease by measurement of S100 protein in serum: prospective case-control study
Diagnosis of Creutzfeldt-Jakob disease by measurement of S100 protein in serum: prospective case-control study Markus Otto, Jens Wiltfang, Ekkehard Schütz, Inga Zerr, Anke Otto, Annette Pfahlberg, Olaf
More information